The discovery of a class of novel HIV-1 maturation inhibitors and their potential in the therapy of HIV.

Published

Journal Article (Review)

Although HIV infection is now primarily treated with reverse transcriptase and protease inhibitors, HIV therapy must look toward new drugs with novel mechanism(s) of action to both improve efficacy and address the growing problem of drug resistance. Using natural products as a source of biologically active compounds, our drug discovery program has successfully optimised the natural product betulinic acid to the first-in-class maturation inhibitor 3-O-(3',3'-dimethylsuccinyl)-betulinic acid (DSB). DSB's unique viral target has been identified as a late step in Gag processing. Specifically, it inhibits the cleavage of the capsid precursor, CA-SP1, resulting in a block to the processing of mature capsid protein leading to a defect in viral core condensation. DSB represents a unique class of anti-HIV compounds that inhibit virus maturation and provide additional opportunities for anti-HIV therapy. In this review, the discovery of DSB and its mode of action are summarised. Anti-AIDS Agents part 64. For part 63 in the series, see YU D, LEE KH: Recent progress and prospects on plant-derived anti-HIV agents and analogs. In: Medicinal Chemistry of Bioactive Natural Products. XT Liang, WS Fang (Eds), Wiley, New York, USA (2005) (In Press).

Full Text

Duke Authors

Cited Authors

  • Yu, D; Wild, CT; Martin, DE; Morris-Natschke, SL; Chen, C-H; Allaway, GP; Lee, K-H

Published Date

  • June 2005

Published In

Volume / Issue

  • 14 / 6

Start / End Page

  • 681 - 693

PubMed ID

  • 16004596

Pubmed Central ID

  • 16004596

Electronic International Standard Serial Number (EISSN)

  • 1744-7658

Digital Object Identifier (DOI)

  • 10.1517/13543784.14.6.681

Language

  • eng

Conference Location

  • England